(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
02 October 2025 (02.10.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/202979 A1

(51) International Patent Classification:
C07D 401/14 (2006.01) *A61K 31/4709* (2006.01)
C07D 405/14 (2006.01) *A61P 35/00* (2006.01)
C07D 471/04 (2006.01)

(21) International Application Number:
PCT/IB2025/053280

(22) International Filing Date:
28 March 2025 (28.03.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
202441025578 28 March 2024 (28.03.2024) IN

(71) Applicant: **AURIGENE ONCOLOGY LIMITED** [IN/IN]; 39/40(P), KIADB Industrial Area, Electronics City Phase II, Karnataka, Bangalore 560100 (IN).

(72) Inventors: **ABBINENI, Chandrasekhar**; Plot #387, IKI-GAI, Journalists' colony phase 3, Gopanpally, Telangana, Hyderabad 500032 (IN). **SAMAJDAR, Susanta**; R801, HM Tambourine, JP, Nagar 6th Phase, Karnataka, Bangalore 560078 (IN). **TALLURI, Krishna Chaitanya**; Flat no. 401, Srinadha Nilayam, opp. ALIND Employees colony park, Sudarshan Nagar, Lingampalli, Hyderabad 500019 (IN).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *of inventorship (Rule 4.17(iv))*

Published:
— *with international search report (Art. 21(3))*

(54) **Title:** SUBSTITUTED HETEROCYCLIC COMPOUNDS AND THEIR DERIVATIVES AS CBP AND/OR P300 DEGRADERS



(I)

(57) **Abstract:** The present disclosure provides substituted heterocyclic compounds of formula (I) or a pharmaceutically acceptable salt thereof or a stereoisomer thereof, which are therapeutically useful as CBP and/or p300 degraders. These compounds are useful in the treatment and/or prevention of diseases and/or disorders responsive to CBP and/or p300 degradation. Compounds of the present disclosure are especially useful for treating cancer, autoimmune, inflammatory and neurodegenerative diseases and disorders. The present disclosure also provides processes for preparation of the compounds and pharmaceutical formulations comprising at least one of the compounds of formula (I) or a pharmaceutically acceptable salt thereof or a stereoisomer thereof.

WO 2025/202979 A1